Intellia Therapeutics, Inc. (0JBU.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
40 Erie Street
Cambridge, MA 02139
United States of America (the)
Phone
857 285 6200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
403
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| John Leonard | President, Chief Executive Officer & Director | 1.26M | 1957 |
| Michael Dube | VP & Chief Accounting Officer | 478,489 | 1978 |
| Birgit Schultes | Executive VP & Chief Scientific Officer | 708,860 | 1963 |
| James E. Basta | Executive Vice President, General Counsel & Corporate Secretary | 732,367 | 1966 |
| David Lebwohl | Executive Vice President & Chief Medical Officer | 781,359 | 1955 |
| Edward J. Dulac | Executive Vice President, Chief Financial Officer and Treasurer | 853,712 | 1976 |
| Rodolphe Barrangou | Founder and Member of Scientific Advisor Board | 1.38M | N/A |
| Jennifer A. Doudna | Founder and Member of Scientific Advisor Board | 1.38M | 1964 |
| Derrick J. Rossi | Founder and Member of Scientific Advisor Board | 1.38M | N/A |
| Erik J. Sontheimer | Founder and Member of Scientific Advisor Board | 1.38M | N/A |
| Luciano Marraffini | Founder and Member of Scientific Advisor Board | 1.38M | N/A |
| Eliana Clark | Executive VP & Chief Technical Officer | 0 | 1958 |
| Jason Fredette | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Rachel E. Haurwitz | Co-Founder | 0 | 1986 |
Intellia Therapeutics, Inc. is a genome editing company dedicated to discovering and developing therapeutic solutions. Its in vivo pipeline features leading candidates such as NTLA-2001, currently undergoing Phase 1 clinical evaluation for transthyretin amyloidosis, and NTLA-2002, designed to address hereditary angioedema. The company also pursues a range of liver-targeted initiatives, addressing conditions including hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Complementing their in vivo efforts, Intellia's ex vivo pipeline includes NTLA-5001 for acute myeloid leukemia. Additionally, they have proprietary programs focused on engineering cell-based therapies for a spectrum of oncological and autoimmune diseases. Central to their platform is the versatile Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia maintains a network of strategic collaborations, including agreements with Novartis Institutes for BioMedical Research to engineer hematopoietic stem cells for sickle cell disease treatment, and with Regeneron Pharmaceuticals for co-developing potential therapies for hemophilia A and B. Further partnerships involve Ospedale San Raffaele, and a strategic alliance with SparingVision SAS to create novel genomic medicines using CRISPR/Cas9 for ocular diseases. Founded in 2014 as AZRN, Inc., the company is headquartered in Cambridge, Massachusetts.